MA43879A - Modulation des rã‰cepteurs couplã‰s aux protã‰ines g (rcpg) par les imipridones - Google Patents
Modulation des rã‰cepteurs couplã‰s aux protã‰ines g (rcpg) par les imipridonesInfo
- Publication number
- MA43879A MA43879A MA043879A MA43879A MA43879A MA 43879 A MA43879 A MA 43879A MA 043879 A MA043879 A MA 043879A MA 43879 A MA43879 A MA 43879A MA 43879 A MA43879 A MA 43879A
- Authority
- MA
- Morocco
- Prior art keywords
- imipridones
- gpcr
- modulation
- receptors
- protected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2016/015817 WO2016123571A1 (fr) | 2015-01-30 | 2016-01-29 | 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogues et sels de ce composé et leur utilisation en thérapie |
US201662308325P | 2016-03-15 | 2016-03-15 | |
US201662425403P | 2016-11-22 | 2016-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43879A true MA43879A (fr) | 2018-12-05 |
Family
ID=59398848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043879A MA43879A (fr) | 2016-01-29 | 2017-01-30 | Modulation des rã‰cepteurs couplã‰s aux protã‰ines g (rcpg) par les imipridones |
Country Status (14)
Country | Link |
---|---|
US (2) | US11116771B2 (fr) |
EP (1) | EP3408298A4 (fr) |
JP (2) | JP7030701B2 (fr) |
KR (1) | KR20180125460A (fr) |
CN (2) | CN115844895A (fr) |
AU (2) | AU2017211423B2 (fr) |
BR (1) | BR112018015590A2 (fr) |
CA (1) | CA3013044A1 (fr) |
IL (2) | IL260815B (fr) |
MA (1) | MA43879A (fr) |
MX (2) | MX2018009227A (fr) |
NZ (1) | NZ745425A (fr) |
SG (2) | SG11201806401YA (fr) |
WO (1) | WO2017132661A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10172862B2 (en) * | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
US20210125683A1 (en) * | 2017-09-15 | 2021-04-29 | The Regents Of The University Of California | Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring |
WO2019067709A1 (fr) * | 2017-09-27 | 2019-04-04 | The Regents Of The University Of California | Gpcr dans des fibroblastes associés au cancer |
US20210038561A1 (en) | 2018-01-31 | 2021-02-11 | Mayo Foundation For Medical Education And Research | Methods of treating fibrotic pathologies |
CN112739332A (zh) * | 2018-04-09 | 2021-04-30 | 奥尔吉尼西丝公司 | 生物体颗粒、氧化还原体、方法和组合物 |
CN109157656B (zh) * | 2018-10-15 | 2021-08-27 | 重庆医科大学附属永川医院 | 一种双靶标肿瘤疫苗及其制备方法和应用 |
KR102403686B1 (ko) | 2020-05-15 | 2022-05-31 | 뉴로핏 주식회사 | 뇌자극 위치 제공장치 및 방법 |
BR112023002082A2 (pt) | 2020-08-06 | 2023-05-09 | Eoetvoes Lorand Tudomanyegyetem | Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena |
CN112402439A (zh) * | 2020-11-18 | 2021-02-26 | 西安组织工程与再生医学研究所 | miR-325核酸类似物在制备改善肝胶原沉积相关产品中的应用 |
US11648248B1 (en) | 2022-01-12 | 2023-05-16 | King Abdulaziz University | Potent antimicrobial compounds with a pyridazine nucleus |
WO2024031030A2 (fr) * | 2022-08-03 | 2024-02-08 | Shi Xiandong | Procédé quantitatif pour déterminer un état mental fondé sur drd1 et/ou drd5, et son application |
CN115531378B (zh) * | 2022-10-19 | 2023-10-13 | 中国医学科学院医药生物技术研究所 | Pht427作为ndm-1与kpc-2双重抑制剂的应用 |
CN116731136B (zh) * | 2023-08-04 | 2023-12-05 | 齐鲁工业大学(山东省科学院) | H3k23a组蛋白点突变在提高酿酒酵母乙酸耐受性及木糖发酵性能中的应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2150062A1 (de) | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
WO2004082570A2 (fr) * | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics et traitements contre des maladies associees au recepteur d2 de la dopamine (drd2) |
EP1644536A4 (fr) * | 2003-07-08 | 2008-07-23 | Univ California | Marqueur genetique de reponse a des antipsychotiques atypiques et a des antidepresseurs et leurs methodes d'utilisation |
US8088895B2 (en) * | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
EP2197340A4 (fr) | 2007-09-19 | 2015-10-21 | Oncofluor Inc | Procédé d'imagerie et de traitement d'organes et de tissus |
JP2014509323A (ja) * | 2011-02-28 | 2014-04-17 | マックマスター ユニヴァーシティ | ドーパミン受容体遮断薬による癌の処置 |
PL2701708T3 (pl) * | 2011-04-29 | 2020-11-02 | The Penn State Research Foundation | Indukcja genu drobnocząsteczkowego trail przez komórki zdrowe i komórki nowotworowe jako terapia przeciwnowotworowa |
RS59013B1 (sr) | 2013-03-13 | 2019-08-30 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u lečenju kancera |
US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
WO2015073072A1 (fr) | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
US9376437B2 (en) * | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
EP3068401B1 (fr) * | 2013-11-15 | 2019-02-27 | Oncoceutics, Inc. | 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, ses sels et procédés d'utilisation |
US10239877B2 (en) * | 2014-03-31 | 2019-03-26 | The Scripps Research Institute | Pharmacophore for trail induction |
HUE052821T2 (hu) * | 2015-01-30 | 2021-05-28 | Oncoceutics Inc | 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása |
CN104860948B (zh) * | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
-
2017
- 2017-01-30 MX MX2018009227A patent/MX2018009227A/es unknown
- 2017-01-30 MA MA043879A patent/MA43879A/fr unknown
- 2017-01-30 SG SG11201806401YA patent/SG11201806401YA/en unknown
- 2017-01-30 CN CN202211658374.3A patent/CN115844895A/zh active Pending
- 2017-01-30 CN CN201780015327.8A patent/CN109311980B/zh active Active
- 2017-01-30 KR KR1020187024948A patent/KR20180125460A/ko active Search and Examination
- 2017-01-30 WO PCT/US2017/015608 patent/WO2017132661A2/fr active Application Filing
- 2017-01-30 BR BR112018015590A patent/BR112018015590A2/pt unknown
- 2017-01-30 NZ NZ745425A patent/NZ745425A/en unknown
- 2017-01-30 EP EP17745078.0A patent/EP3408298A4/fr active Pending
- 2017-01-30 AU AU2017211423A patent/AU2017211423B2/en active Active
- 2017-01-30 JP JP2018540011A patent/JP7030701B2/ja active Active
- 2017-01-30 SG SG10202108306UA patent/SG10202108306UA/en unknown
- 2017-01-30 US US16/073,228 patent/US11116771B2/en active Active
- 2017-01-30 CA CA3013044A patent/CA3013044A1/fr active Pending
-
2018
- 2018-07-26 IL IL260815A patent/IL260815B/en unknown
- 2018-07-27 MX MX2023004443A patent/MX2023004443A/es unknown
-
2021
- 2021-07-29 US US17/388,551 patent/US20220072001A1/en active Pending
- 2021-10-03 IL IL286923A patent/IL286923A/en unknown
- 2021-12-10 JP JP2021200772A patent/JP2022046528A/ja active Pending
-
2022
- 2022-01-28 AU AU2022200583A patent/AU2022200583B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2023004443A (es) | 2023-05-08 |
SG10202108306UA (en) | 2021-08-30 |
MX2018009227A (es) | 2018-11-09 |
JP7030701B2 (ja) | 2022-03-07 |
US20190307751A1 (en) | 2019-10-10 |
US20220072001A1 (en) | 2022-03-10 |
IL260815B (en) | 2021-10-31 |
NZ745425A (en) | 2023-03-31 |
EP3408298A4 (fr) | 2019-09-04 |
SG11201806401YA (en) | 2018-08-30 |
CN109311980A (zh) | 2019-02-05 |
US11116771B2 (en) | 2021-09-14 |
AU2017211423A1 (en) | 2018-09-06 |
AU2022200583B2 (en) | 2024-05-02 |
AU2022200583A1 (en) | 2022-02-24 |
EP3408298A2 (fr) | 2018-12-05 |
WO2017132661A3 (fr) | 2017-08-31 |
JP2022046528A (ja) | 2022-03-23 |
BR112018015590A2 (pt) | 2019-10-01 |
JP2019511460A (ja) | 2019-04-25 |
IL286923A (en) | 2021-10-31 |
CN109311980B (zh) | 2023-01-17 |
KR20180125460A (ko) | 2018-11-23 |
CN115844895A (zh) | 2023-03-28 |
AU2017211423B2 (en) | 2021-10-28 |
CA3013044A1 (fr) | 2017-08-03 |
WO2017132661A2 (fr) | 2017-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43879A (fr) | Modulation des rã‰cepteurs couplã‰s aux protã‰ines g (rcpg) par les imipridones | |
CL2017001361A1 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
EA201691974A1 (ru) | Антитела против ox40 и способы их применения | |
DK3318754T3 (da) | Trykgenererende indretning af Magnus-typen | |
DK3689899T3 (da) | Kimære mnd-promotor-antigenreceptorer | |
DK3126499T3 (da) | Sammensætninger til modulering af sod-1-ekspression | |
DK3597663T3 (da) | Kimære antigenreceptorer af anti-cd70 | |
DK3532486T3 (da) | Antistof-forbundne cykliske peptidtyrosin-tyrosinforbindelser som modulatorer af neuropeptid-y- receptorer | |
DK3119888T3 (da) | Sammensætninger til at modulere ataxin-2-ekspression | |
DK3277722T3 (da) | Antistoffer mod canin interleukin-4 receptor alpha | |
BR112016016017A2 (pt) | métodos para gerar um fluxo de atividades | |
DK3125942T3 (da) | Forstøvning af immunoglobulin | |
DK3250521T3 (da) | Brænder til undervandsforbrændingssmelteovn | |
DK2926897T3 (da) | Anordning til genindvinding af halogenerede carbonhydrider | |
DK3484880T3 (da) | Heteroaromatiske modulatorer af retinoid-relateret orphan receptor gamma | |
EA201790428A1 (ru) | Синтез энт-прогестерона и его промежуточных соединений | |
DK3161136T3 (da) | Fremgangsmåde til berigelse af mikrovesikler | |
DK2965765T3 (da) | Anvendelse af adelmidrol til behandling af epiteldysfunktioner | |
DK3190088T3 (da) | Fremgangsmåde til syntese af ammoniak | |
DK3448853T3 (da) | Forbindelser til modulering af aquaporiner | |
DK3306031T3 (da) | Anordning til forlængelse af udmattelseslevetid | |
BR112017009455A2 (pt) | controle de afogador do pistão | |
FR3028701B1 (fr) | Dispositif de generation de rushes cinematographiques par analyse video | |
DK2923690T3 (da) | Sammensætning til stabilisering af lysfølsomme forbindelser | |
FR3038344B1 (fr) | Assemblage aubage utilisant un emboitement |